like ended XX, for I'd XXXX. to everyone welcome Thank call quarter to March the first you, our Susan.
weeks. call few allowance fourth was the us mid-March, year-end Clearly, the quarter XXXX ago an nearly those FDA oral as just most noteworthy failed made we who therapies. held in quarter and pan-FLTX have first-in-class progress in clinical event pan-BTK significant the and it, or during While in will of a non- developed our CG-XXX [indiscernible] Aptose has inhibitors for weeks conference standard I human intolerant call first the trial or being covalent are trial XXX initiate first this to to
In a detail trial AML with few and minutes. I'll with in MDS, and for have that XXX patients addition, explain planned in second we further
In lowest APTO-XXX we in molecules during addition MYC clinical with questions. in call, XXX. clinical to clinical with you XXX, the XXX, On both AML development. first discuss MYC the on the Aptose an dose call and this news But programs, discuss progress reduce With expression could that administered. illustrating made the has XXX at timelines small quarter progress let's the quarterly first, now in to and our of your our we'll inhibitor open patient year, data presented anticipated two our and the brief review today's financials well-differentiated status our then plan XXX, XXX for
results screening As been release the underway. first trial for we that QX thrilled has today, the patient are we in XXX with our announced clinical initiated earlier XXXX first is and press
this and time very drug is high for this have We a us. for expectations exciting
plasma milligrams, levels; XXX three dose milligrams dose of two tolerated. II bid no which for milligrams, we cohorts, planned administered safely escalation a with milligrams XXX first is by XXX the active each to be cells recommended time other determine will recommended planned in standard longer the NHL, of with the Our to patient ascending XXX during include; administer the patients as of kill In that and XX dose-escalation lymphocytic treatment on target or for the SLL days, that mutant forms to every Phase for assay, for or cancer milligrams, to determine to or in XXX relapsed X) patients, phase phospho milligram, of and X) X) inhibits CLL, milligrams lowest in a XXX CCLX titration BTK, activation; with and dose. sufficient up refractory inhibit we'll dosing DNA expansion markers by plasma and XXX planned chronic markers to MTD B-cell series survive, or at tolerance or a or the kinases CCLX dose we trial a that well XXX, we population this then malignancy accelerated indicate and potentially other changes and or can the FDG milligrams me, are treatment to NHL. trial. dose clinical the for been but thereafter oral leukemia and response I after allowed samples; tolerability at dose potently which levels identified XXX Ia/Ib look one and tumor XXX dose small clinical with are key three or Because [ph] XXX levels points has of trial oncogenic as a and the XXX and XXX suppress administered to see in patient status. and calls if scans starting and excuse scheme. for These clinical this safe with can serum receptor followed effectiveness pathways. PET volume also hours measurement for properties of either B-cell pharmacokinetics, albeit of is B-cell BTK and has are of an PK, circulating The the II uniquely XX X) -- and to markers disease or wild-type for effective activity open-label the failed, viewed both signals has of XXX six samples; protocol the PIA tumor at longer CLL Phase no for SLL, patients hope cancers evaluate X) patient as availability required trial depending safety of vitro, treatment in lymphoma multi-center inhibitory non-Hodgkin's at be Phase our XXX lymphocytic of safety patients benefit intent the on including the CLL, and as measure watch level Phase a to by oncogenic pathways determine lymphoma CXXS XXX biologically cooling; proteins and the patient phospho different of Once will only to of capsules tumor
want the also time we this that to humans still will exist. enter you first However, risks XXX and certain remind is
questions humans plan acutely unexpected begun. in molecules toxicity other was with certain doses standard of FLTX FLTX although possible the be with plasma animal expected malignancies. was a than that care likelihood allowance preclinical mutant patients for on for all in was as final approved regarding humans Likewise, not this committed of it an potent and killing perform concentration in forms inhibit could clinical XXX initiate near-term at gilteritinib well is B-cell XXX to hematology cells These rapidly the will is is instance, now ability be potentially we may hope is XXX in information the is to from observed the answer likely, cancer studies. as circumvents, X,XXX these on pharmacokinetics to to to times be MDS. therapeutically that as of response demonstrate different seek study in that shown the that more quizartinib, truly was to drugs first-in-human AML the in in in patients AML-MDS non-efficacious from to approved to patients precision potential patient dose has clinical capacity XXX The present XXX finally dosing and with in trials. hand the very Plus, preclinical B-cell the that approved and to directly that FDA year of cells be to AML achieved inhibitor avoids B-cell study AML we in XXXX. with specific average approximately AML locations and more emerge XXX. trial will population. have with XX development. studies that to FLTX and trial meaning identify the PK, to points those achieves and resistant patients and models in and clinical we be findings the For all way killing and this in have efficacy capacity cancer This only the Indeed, molecule available position sites We increases other the and a may and in And at once potent to safety potently The and update. for than screening clinical kinases animal XXX patients, few treating a More XXX treat BTK, patients findings to that to continue toxicities times on upcoming AML other active we XXX. or differentiates strategy or current mutations FLTX already inhibitors clinicaltrials.gov ibrutinib,
many preclinical translate data clinic. inhibitors with inhibitors market, demonstrated generally on with preclinical work the As kinase tyrosine other kinase well in the to
durable have the data animal Meeting most a our yes-cures XXX's advisers that for difficult-to-treat XXX report [ph] superior to case. later that is Society us models as year showing ASH for at like compelling in and For elimination potency great clinical to in hematologic certainly scientific patients malignancies. and cancer, potentially enthusiasm investigators December. the option tumor the in profile hope hope is drug or gives of Hematology XXX potential Indeed, we American the We with therapeutic our
APTO-XXX I call on update of the it. Now, or let as you me just status XXX, will
patients MYC inhibit MYC a a and MDS. anticancer oncogene a the of the compound cell stage host AML. the treatment Phase and that only that a potential Our of for is of malignancies may currently driver molecules hematologic the trial can solid clinical known major tumor have as among proliferation, indications. in for application oncology, on certain a Inhibition MYC directly suggests cancer AML I XXX inhibitor expression with broader
is XXX weekly up MDS or in and patients is in The by with the to we being combination study is to relapsed last AML XX-day XX our to administered followed once MDS AML expansion enroll cohorts As patients. over and and refractory cycle transition mentioned call, high-risk single-agent study then studies. expected designed
in reported previously, first study. we As dosed successfully patient the this
XX meter XX over mgs dose received the and favorably. tolerated per Our of square patient was days weekly once the lowest drug first
analyses and we In engagement. target and pXX addition, patient MYC that of evidence biomarker we perform expression observed from
sites total in actively XX of was hours which screening clinical with when clear trend after MYC is in cycle, XX% downward gene During a expression amount measured number each gene have reduction the of patients. currently than expression consistent the a all engagement. We for reduced MYK with dose, week and greater a XX-day and each the PBMCs target of
we As dose this have in high-performance a in that also. and patient mentioned to find sick a been is population very process past, we've second disciplined the the for level
we reminder, to of a choose that further additional high-performance no required to each a one we SAEs first patient at to are need cycle, so patients. important dose escalation. two to provided evaluate only entire expand It's there that are the not dose to As at proceeding to XX-day patient level complete levels before will the dose
Towards the dose tolerates that patient squared, this treatment the hope from dose the per report goal, first MDS twice at we dosing can now and level the with receives of XXX. that dose and of initiated benefit patient XX second has mgs XXX we density level an meter
regarding candid we're XXX if know, to communications any of you developments. updated the keep As and there XXX, transparent continue and new development in our we'll are you both
and to to focus in Research for understand to month Cancer to AACR Atlanta. American the presented like clinic, the meeting perform or last studies our review non-clinical we and now better of preclinical to of at compare drugs agents. XXX action was that I'd quickly is our competitive the on Now, Association mechanisms Though research just continue XXX
We profile initiative, Brian Cancer samples we've and samples patients described cells the other Dr. and extensively insights keen beat Druker Society. of Leukemia cells to provide combination As other to AML, actual patient's in compound's with human the spearheaded Knight XXX Institute hundreds providing and the the Lymphoma and by AML collaborative alone Beat OHSU The a team with & his against in activity XXX groundbreaking agents. -- from initiative primary hematologic from against malignancies, able through a past with the AML research
superior demonstrated the CG-XXX, potency We is key to relative IDHX entitled against poster, specific subgroups with other abnormalities risk dovitinib, will title. of related that our refractory approved hematology as groups demonstrates sorafenib, you patients. inhibitor markets. inhibitors can drugs significant and XXX at genetic includes prognosis that potency of Events the quizartinib, those in highlight gilteritinib, section. of profiles XXX crenolanib and to also poster website, across can large pan-FLTX/pan-BTK a in assess and end when here; potency AML cells AML poor effectiveness on AML, cells www.aptoes.com a which FLTX look relapsed and some it's non-favorable other to address mutant midostaurin, AML superior I Described including drugs Presentations findings the of The genetic patients. development in compared take sunitinib, from and
Our patient that sensitivity accelerated for the AML for of Dr. with expected with venetoclax. granted venetoclax, drug last synergistically Druker's in B-cell with The that possible an combination demonstrated it is mutations data results approval. RXXX poster with and AML cells accelerated poster approval combination The in XXX were with In highlights XXX mutations opportunities the suggest populations. year samples, patient IDHX to certain future treatment the enhanced Venetoclax acted studies presented and of sensitivity the potential with results described were was and certain also malignancies. in of venetoclax for which to Also for of set combination cancer GLP combination was poster unexpected the primary studies. patients patient with of studies XXX killing safety could the from XX-day greater and with of FLTX-ITD cells presents a have toxicokinectic finding XXX, become choice combination a us of in populations.
Raji asked finding wealth favorable interest XXX to testing strongly safety data which at continue often market to a that three competitive these, concentrations in high that MYC-driven larger of XXX years the conferences. clearly A develop to demonstrated companies cells multiple initiate development. oncogene The and continues level human-derived to the place among studies XXX. vitro XXX generated XXX supports We're of Importantly, make to leading required clinical the molecule in drug's demonstrate the increasing tumor define AACR apoptosis, about further later-stage target and required primary to and to the in compounds Data additional patients. of for described the landscape poster Aptose's again much MYC The differentiate have like that inhibits us small how in grow and in mechanism the enabled I tremendous action solid expression a to of caps. team excited clinic we non-covalent to In to and with potential safety pointing on hematologic cells on in -- be and profile. the order modifications cells. resistance At long-term if also also of In to AACR, CG-XXX XXX. but this data might remarks report XXX. performed best-in-class year-end. regarding have our we develop of in studies gene that want hope cancer website. inhibitor data drug to resistance is resistance, to this to words, evolvement generate BTK compound how as to resistance. the development, FLTX Again, in near and The our study, XXX, early the poster a quickly XXX have to you were kinase we clinical XXX. in believe other multi-kinase multi-cluster available we determine vitro presented we're robust a cells we with also finally trying MYC profile, induce MYC
that were have Association, are an at Hematology submitted presentation collaborators accepted prolific research EHA, been data, been the to European in the abstract June. their notified and publishing conference we presenting for just and in Our that has
we detail once will presence later So this time. again have additional form at at and a we important a provide
Conference week conference. the the Burton Investor On last presented at front, we Bloom
presentations call Executive Webcasts at Oncology Conference Healthcare Summit President I will later who presenting website. quarter. our Chief We the RBC month. our and Greg for turn be on Officer, to and results the will review Financial Mr. this now over Insight the will the will be Oppenheimer Chow, and Vice
